Tianqin Mao

Tianqin Mao

Auto-generated profile, based on publicly available information

Tianqin Mao

Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, P.R. China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
HWHong Wu
Hong Wu
XLXuefeng Leng
Xuefeng Leng
QLQianshi Liu
Qianshi Liu
TMTianqin Mao
Tianqin Mao
Tao JiangTao Jiang
Tao Jiang
CXChuan Xu
Chuan Xu
Neoadjuvant chemoimmunotherapy (NACI) has shown promise in the treatment of resectable esophageal squamous cell carcinoma (ESCC). The microbiomes of patients can impact therapy response, and previous studies have demonstrated that intestinal microbiota influences cancer immunotherapy by activating gut immunity. Here, we investigated the effects of intratumoral microbiota on the response of patients with ESCC to NACI. Intratumoral microbiota signatures of β-diversity were disparate and predicted the treatment efficiency of NACI. The enrichment of Streptococcus positively correlated with GrzB+ and CD8+ T-cell infiltration in tumor tissues. The abundance of Streptococcus could predict prolonged disease-free survival in ESCC. Single-cell RNA sequencing demonstrated that responders displayed a higher proportion of CD8+ effector memory T cells but a lower proportion of CD4+ regulatory T cells. Mice that underwent fecal microbial transplantation or intestinal colonization with Streptococcus from responders showed enrichment of Streptococcus in tumor tissues, elevated tumor-infiltrating CD8+ T cells, and a favorable response to anti-PD-1 treatment. Collectively, this study suggests that intratumoral Streptococcus signatures could predict NACI response and sheds light on the potential clinical utility of intratumoral microbiota for cancer immunotherapy. Significance: Analysis of intratumoral microbiota in patients with esophageal cancer identifies a microbiota signature that is associated with chemoimmunotherapy response and reveals that Streptococcus induces a favorable response by stimulating CD8+ T-cell infiltration. See related commentary by Sfanos, p. 2985

16 September 2024
Verified
Other
Open access
HWHong Wu
Hong Wu
XLXuefeng Leng
Xuefeng Leng
QLQianshi Liu
Qianshi Liu
TMTianqin Mao
Tianqin Mao
Tao JiangTao Jiang
Tao Jiang
CXChuan Xu
Chuan Xu
Neoadjuvant chemoimmunotherapy (NACI) has shown promise in the treatment of resectable esophageal squamous cell carcinoma (ESCC). The microbiomes of patients can impact therapy response, and previous studies have demonstrated that intestinal microbiota influences cancer immunotherapy by activating gut immunity. Here, we investigated the effects of intratumoral microbiota on the response of ESCC patients to NACI. Intra-tumoral microbiota signatures of β-diversity were disparate and predicted the treatment efficiency of NACI. The enrichment of Streptococcus positively correlated with GrzB+ and CD8+ T cell infiltration in tumor tissues. The abundance of Streptococcus could predict prolonged disease-free survival in ESCC. Single-cell RNA sequencing (scRNA-seq) demonstrated that responders displayed a higher proportion of CD8+ effector memory T cells but a lower proportion of CD4+ Treg cells. Mice that underwent fecal microbial transplantation (FMT) or intestinal colonization with Streptococcus from responders showed enrichment of Streptococcus in tumor tissues, elevated tumor-infiltrating CD8+ T cells, and a favorable response to anti-PD-1 treatment. Collectively, this study suggests that intratumoral Streptococcus signatures could predict NACI response and sheds light on the potential clinical utility of intratumoral microbiota for cancer immunotherapy.

24 November 2025
Verified
Other
Open access
HWHong Wu
Hong Wu
XLXuefeng Leng
Xuefeng Leng
QLQianshi Liu
Qianshi Liu
TMTianqin Mao
Tianqin Mao
Tao JiangTao Jiang
Tao Jiang
CXChuan Xu
Chuan Xu
Table S1 shows clinical characteristics of esophageal squamous cell carcinoma (ESCC) patients who underwent upfront surgery.

24 November 2025
Verified
Other
Open access
HWHong Wu
Hong Wu
XLXuefeng Leng
Xuefeng Leng
QLQianshi Liu
Qianshi Liu
TMTianqin Mao
Tianqin Mao
Tao JiangTao Jiang
Tao Jiang
CXChuan Xu
Chuan Xu
Figure S4 shows intra-tumoral bacteria identified in patients with ESCC.

24 November 2025
Verified
Other
Open access
HWHong Wu
Hong Wu
XLXuefeng Leng
Xuefeng Leng
QLQianshi Liu
Qianshi Liu
TMTianqin Mao
Tianqin Mao
Tao JiangTao Jiang
Tao Jiang
CXChuan Xu
Chuan Xu
Table S2 shows clinical characteristics of patients with esophageal squamous cell carcinoma (ESCC) who underwent NACI1 treatment.

24 November 2025
Verified
Other
Open access
HWHong Wu
Hong Wu
XLXuefeng Leng
Xuefeng Leng
QLQianshi Liu
Qianshi Liu
TMTianqin Mao
Tianqin Mao
Tao JiangTao Jiang
Tao Jiang
CXChuan Xu
Chuan Xu
Table S4 shows reagents and antibodies.